Clinical Coagulation, Malmö
21 – 30 of 662
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Low bleeding rates after intramuscular Covid-19 vaccination in patients with haemophilia and von Willebrand disease : Outcome data from the Swedish haemophilia registry
- Contribution to journal › Debate/Note/Editorial
-
Mark
Future needs for continuing innovation in hemophilia : improving outcomes for individuals of all severities, including women and those in resource-constrained regions
- Contribution to journal › Scientific review
-
Mark
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
- Contribution to journal › Article
-
Mark
Recombinant FVIII replacement products for haemophilia A : An updated valuation by indirect comparison measuring area under the curve
- Contribution to journal › Debate/Note/Editorial
-
Mark
Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults : A population-based cohort study
- Contribution to journal › Article
-
Mark
Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study)
- Contribution to journal › Article
-
Mark
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal
(2024) In Haemophilia
- Contribution to journal › Article
-
Mark
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
(2024) In Haemophilia
- Contribution to journal › Article
-
Mark
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria
- Contribution to journal › Article
-
Mark
Preface
(2024)
- Chapter in Book/Report/Conference proceeding › Foreword/Postscript
